Literature DB >> 15076627

Gastrointestinal and other clinical manifestations in 17 children with congenital disorders of glycosylation type Ia, Ib, and Ic.

Gerard Damen1, Hans de Klerk, Jan Huijmans, Jan den Hollander, Maarten Sinaasappel.   

Abstract

OBJECTIVES: The typical signs and symptoms of congenital disorders of glycosylation (CDG) include dysmorphy, failure to thrive, and neurologic abnormalities. However, more and more children diagnosed at a young age are not dysmorphic and do not have neurologic involvement. The authors studied the gastrointestinal and other clinical manifestations of CDG type Ia, Ib, and Ic.
METHODS: As of January 2003, 17 children were identified with CDG at the authors' institution. The medical records of the patients were reviewed.
RESULTS: Five children had CDG Ia, three children CDG Ib, and nine children CDG Ic. Age at diagnosis ranged from 2 months to 15 years. Failure to thrive was present in 80% of patients with CDG Ia, in 66% of those with CDG Ib, and in 11% of those with CDG Ic. Five children had protein-losing enteropathy (two CDG Ia, two CDG Ib, and one CDG Ic). Hepatomegaly was present in 40% of patients with CDG Ia, in 66% of those with CDG Ib, and in 11% of those with CDG Ic. In CDG Ic, hepatomegaly was transient. In CDG Ia, histologic analysis of the liver showed swollen hepatocytes, steatosis, and fibrosis. In CDG Ib, hamartomatous collections of bile ducts were seen. In one patient with CDG Ib, the clinical picture was restricted to congenital hepatic fibrosis for more than a decade.
CONCLUSIONS: The study confirms the heterogeneity of the clinical picture in children with CDG type Ia, Ib, and Ic. Children with protein-losing enteropathy should be tested for CDG. Protein-losing enteropathy can be caused, not only by CDG Ia and Ib, but also by type Ic. Children with congenital hepatic fibrosis should be tested for CDG, even in the absence of other symptoms. In CDG Ib, histologic analysis of the liver showed hamartomatous collections of bile ducts (Meyenburg complex).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15076627     DOI: 10.1097/00005176-200403000-00010

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  24 in total

1.  [Dysmorphia and psychomotor retardation].

Authors:  T Struffert; E M Feldmann; O Schofer; W Reith
Journal:  Radiologe       Date:  2005-03       Impact factor: 0.635

Review 2.  Long-standing mild hypertransaminasaemia caused by congenital disorder of glycosylation (CDG) type IIx.

Authors:  P L Calvo; S Pagliardini; M Baldi; A Pucci; L Sturiale; D Garozzo; T Vinciguerra; C Barbera; J Jaeken
Journal:  J Inherit Metab Dis       Date:  2008-12-09       Impact factor: 4.982

3.  Protein inhibitor of activated STAT1 interacts with and up-regulates activities of the pro-proliferative transcription factor Krüppel-like factor 5.

Authors:  James X Du; C Chris Yun; Agnieszka Bialkowska; Vincent W Yang
Journal:  J Biol Chem       Date:  2006-12-18       Impact factor: 5.157

4.  ALG6-CDG in South Africa: Genotype-Phenotype Description of Five Novel Patients.

Authors:  M Dercksen; A C Crutchley; E M Honey; M M Lippert; G Matthijs; L J Mienie; H C Schuman; B C Vorster; J Jaeken
Journal:  JIMD Rep       Date:  2012-07-01

5.  Lymphatic edema in congenital disorders of glycosylation.

Authors:  Ruud Hj Verstegen; Miranda Theodore; Hans van de Klerk; Eva Morava
Journal:  JIMD Rep       Date:  2011-10-20

6.  Deficiency of Subunit 6 of the Conserved Oligomeric Golgi Complex (COG6-CDG): Second Patient, Different Phenotype.

Authors:  S Huybrechts; C De Laet; P Bontems; S Rooze; H Souayah; Y Sznajer; L Sturiale; D Garozzo; G Matthijs; A Ferster; J Jaeken; P Goyens
Journal:  JIMD Rep       Date:  2011-11-02

7.  Clinical utility gene card for: ALG6 defective congenital disorder of glycosylation.

Authors:  Jaak Jaeken; Dirk Lefeber; Gert Matthijs
Journal:  Eur J Hum Genet       Date:  2014-07-23       Impact factor: 4.246

8.  DMP1-CDG (CDG1e) with Significant Gastrointestinal Manifestations; Phenotype and Genotype Expansion.

Authors:  C Bursle; D Brown; J Cardinal; F Connor; S Calvert; D Coman
Journal:  JIMD Rep       Date:  2016-08-02

9.  Metabolic liver diseases presenting with neonatal cholestasis: at the crossroad between old and new paradigms.

Authors:  Helena Moreira-Silva; Inês Maio; Anabela Bandeira; Esmeralda Gomes-Martins; Ermelinda Santos-Silva
Journal:  Eur J Pediatr       Date:  2019-01-28       Impact factor: 3.183

Review 10.  Consensus guideline for the diagnosis and management of mannose phosphate isomerase-congenital disorder of glycosylation.

Authors:  Anna Čechová; Ruqaiah Altassan; Delphine Borgel; Arnaud Bruneel; Joana Correia; Muriel Girard; Annie Harroche; Beata Kiec-Wilk; Klaus Mohnike; Tiffany Pascreau; Łukasz Pawliński; Silvia Radenkovic; Sandrine Vuillaumier-Barrot; Luis Aldamiz-Echevarria; Maria Luz Couce; Esmeralda G Martins; Dulce Quelhas; Eva Morava; Pascale de Lonlay; Peter Witters; Tomáš Honzík
Journal:  J Inherit Metab Dis       Date:  2020-04-21       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.